Galapagos | GLPG - Sales Revenues


Galapagos reported EUR900.82M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
argenx SE USD 1.12B 132.91M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Genmab DKK 1.06B 36M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
GRIFOLS EUR 1.98B 110M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Merck EUR 5.25B 70M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 4.25B 764M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025